Background: Genome sequencing coupled with electronic heath record data can uncover medically important genetic variation. Interpretation of rare genetic variation and its role in mediating cardiovascular phenotypes is confounded by variants of uncertain significance.
Introduction
Genetic information is increasingly being used in medical decision making, especially for familial cancers and cardiovascular diseases where the identification of rare genetic variants can inform care for patients and family members at risk (1) (2) (3) . Genetic variants segregating with disease are interpreted as pathogenic or likely pathogenic, and this type of genetic information is diagnostic and useful for clinical management (4) . Variants of uncertain significance (VUS) are those genetic variants about which there is insufficient information to adjudicate a pathogenic or benign classification. The VUS designation often arises for rare or unreported missense variants, and this designation is of low medical utility, as its pathogenic status is unknown (4) .
To improve the reliability of genetic interpretation, the ClinVar database was developed as an online catalog of genetic variation relevant for human health (https://www.ncbi.nlm.nih.gov/clinvar) (5) . Genetic testing laboratories regularly contribute to and update ClinVar's compendium of human health variation. ClinVar, combined with data from large de-identified population sequence databases, is enhancing clinical genetic testing interpretation.
The American College of Medical Genetics and Genomics (ACMG) designated 59 genes as having variation that is medically actionable when the variation is classified as pathogenic or likely pathogenic (6, 7) . Not all variation in the ACMG genes is actionable, since some variants are found at high population frequency, thus making their designation benign or likely benign.
Uncertain variants are neither pathogenic or benign. However, it can be expected that some of these uncertain variants are, in fact, medically important. It has been recommended to return known pathogenic and likely pathogenic results for the actionable genes, even for biobank participants (8) (9) (10) . Variants of uncertain significance are not typically reported and returned to biobank participants, as the risks associated with these variants have not been determined.
Race and population diversity influence the interpretability of genetic testing results (11) (12) (13) .
We used whole genome sequencing (WGS) on a diverse cohort of biobank participants from a single metropolitan site in the US. We assessed genetic variation across self-reported race/ethnicity groups, focusing on medically actionable genes and variants previously reported in ClinVar. We found African ancestry participants have a significantly greater number of variants of uncertain significance compared to participants of European descent. This increase in uncertain variants was present across all genes including the ACMG medically actionable genes and the actionable cardiac genes. We now assessed the prevalence of VUS across this diverse population and examined the association of VUS with echocardiographic indicators of cardiac pathology. Uncertain variants in the cardiac medically actionable genes were significantly associated with changes in left ventricular dimensions. These data underscore the complexities of variant interpretation especially in a diverse population.
Methods

NUgene Cohort
The NUgene biobank includes adult participants who receive care at Northwestern Medicine.
Inclusion and exclusion criteria for participation in the NUgene biobank have been described (14) . Through its participation in the eMERGE (Electronic Medical Records and Genomics) consortium (15, 16) , the NUgene biobank selected 900 participants for whole genome sequencing (WGS). Race/ethnicity was collected using two methods. Approximately 25% of participants used a questionnaire in which race/ethnicity was selected based on multiple general categories including African, Asian (East and South), European, Hispanic, Pacific Islander, Middle Eastern, and Native American ancestry. Participants who completed this questionnaire could select one or more categories. The remaining 75% of patients were classified based on grandparent ancestry using the general categories named above. As the number of individuals who identified as Asian, Asian Indian, Middle Eastern, and Pacific Islander through both methods were low (<1% of the sample), they were reclassified as "Other" and excluded from further analysis. Individuals who self-reported as multi-racial were classified as mixed, and individuals with at least one grandparent who did not classify similarly to the other three grandparents were classified as mixed. For instance, if an individual selected three grandparents as European descent and one grandparent of African ancestry, this individual is classified as mixed.
Whole genome sequencing
WGS was performed on an Illumina XTen machine at the Genome Center at Washington
University School of Medicine yielding >100 GB of data per sample. This depth correlates with >30-fold coverage across the genome providing more even coverage across both noncoding and coding intervals. WGS data from the NUgene cohort was aligned to the human genome reference sequence GRCh37/hg19 using the Burrows-Wheeler Aligner. Variants were called using the Genome Analysis Tool Kit (GATK v3.3.0) (17, 18) . These analyses were conducted using the MegaSeq Pipeline (19) .
Population Structure
The first two components generated by principal component analysis (PCA) were used to estimate global ancestry in the NUgene 900 cohort. PCA was conducted using singular-value decomposition of shared variants in the NUgene cohort with ~5 million biallelic variants distributed across the genome. Coding and noncoding variants were identified using ANNOVAR (20) . Self-reported race was compared to the ancestry groupings determined by the PCA of all variants. An identity by state (IBS) analysis was conducted to identify first relatives within each homogeneous cluster to reduce overfitting in subsequent analytical models. To carry out the IBS analysis, five individuals were removed from the European cluster, one from the African cluster, and four from the Hispanic cluster prior to this analysis to ensure homogeneous race/ethnicity clusters based on visual assessment of PCA graph to classify large outliers. Analyses were carried out using PLINK v1.9 and R v3.5.1.
ClinVar Analysis
Nonsynonymous coding variants were queried and indexed per genome using ClinVar (February 11 th , 2019 adjudication of variants from VCF file) (21) . These analyses included designations of likely pathogenic, pathogenic, pathogenic/likely pathogenic, uncertain significance, and not reported in ClinVar. The ClinVar VCF file used to annotate these variants only included the most recent designation as determined by February 11, 2019. Generalized regression models adjusting for age and sex were used to determine overall differences as well as pairwise differences between self-reported racial/ethnic groups. To correct for differences in the proportion of variants among the self-reported race/ethnicity groups, variants were normalized based on total variant counts per person (an individual's variant count was divided by the individual's total number of variants). Analysis type was determined by the distribution of the outcome variables. In order to correct for multiple testing for the pairwise analysis comparisons, we used the Bonferroni method for correction (22) .
Echocardiogram Analysis with Variants of Uncertain Significance
Echocardiogram, electrocardiogram, and demographic data were queried from the electronic health record, and individual measures were obtained for left ventricular internal diameterdiastole (LVIDd), left ventricular internal diameter-systole (LVIDs), interventricular septal end diastole (IVSDd), and left ventricular ejection fraction (LVEF). The association of longitudinal echocardiogram data and the count of variants of uncertain significance in the cardiac medically actionable genes was calculated. These counts were coded as 0, and ≥1 to reflect the number of variants found in the cardiac actionable genes (as variant counts of 2 were found in only 22 individuals, these counts were recoded as 1). Some participants had multiple echo measurements in a given year. For these participants the median value was used for analysis.
A longitudinal model that controlled for age at echo measurement, sex, and self-reported race/ethnicity with an unstructured covariance matrix was used for analysis with the assumption that missing values were missing at random. Year was used as the time component for this analysis. Race/ethnicity specific analyses were also conducted using a similar model. A sensitivity analysis was conducted using individuals who had an ICD-9 code for cardiomyopathy (ICD-9 425 all subcodes) as above. The longitudinal echocardiogram data and the count of variants not identified in the February 2019 ClinVar database, referred to here as unreported, in the cardiac medically actionable genes were also analyzed using a similar method. Analyses were completed using SAS 9.4 and R v3.5.1.
Results
Genetic diversity in a US metropolitan health care cohort
Through its participation in the eMERGE (Electronic Medical Records and Genomics) consortium (15, 16) , the NUgene biobank selected 900 participants for whole genome sequencing (WGS). The NUgene biobank represents a medical biobank in that the participants receive health care at a single institution. Approximately 23% of these participants were selected based on having diagnostic and/ or procedure codes or medications indicating 1 of 4 conditions of interest to eMERGE investigators: 95 with atopic dermatitis (ICD-9 codes 691.8 and 692.9); 118 with cancer (ICD-9 codes 173-209); 56 with cardiomyopathy (ICD-9 codes 425.1 and 425.4) , and 180 with chronic rhinosinusitis (23) . The other 77% were selected for race/ethnicity. Whole genome sequencing (WGS) was applied to these 900 diverse individuals, and sequencing reads were aligned to the human genome reference sequence GRCh37/hg19 and variants were called using the MegaSeq Pipeline which utilized BWA and GATK best practices. Of the 900 genomes, five were excluded due to sampling error identified through sex mismatch and/or possible sample contamination. The remaining 895 distributed as follows based on self-reported race/ethnicity: African (26%), European (23%), Hispanic (26%), Mixed (24%), or other (1%) ( Table 1 ). Genetic variation correlated with self-reported race/ethnicity.
Individuals of European descent had the lowest number of variants per genome compared to
those in the other groups (4.9M per European descent genome compared to 5.8M per African descent genome, p< 0.05, Figure 1A) . Racially mixed and Hispanic descent individuals had average variant counts between African and European ancestry individuals with counts of 5M and 5.4M, respectively. An identity by state (IBS) analysis was performed and, two pairs of firstdegree relatives were identified with this analysis.
Genomic data was annotated for noncoding and coding variation. As expected, greater than 99% of all genetic variants were noncoding. Considering the nonsynonymous coding variants, the majority were missense variants (79%), and a smaller percentage were stop/loss gain (1.0%), small in-frame insertion/deletions (2.5%), frameshifts (2.5%) and splice sites (15%) (Supplemental Figure 1 ). The number of variants observed only once in the entire data set, a measure of rare variation, was highest in African ancestry participants having, on average, more than any other group (52,865±8,320). European descent participants had the least of any group 
African ancestry subjects have more variants of uncertain significance
Genetic testing is increasingly being used in adult health care settings, but the interpretation of genetic results is complicated by the rare frequency of many genetic variants (24, 25) . Genetic testing is further complicated by the observations that pathogenic and likely pathogenic variants are found at higher frequencies than the diseases specified by these variants (26, 27) . We queried the number of nonsynonymous variants in the NUgene biobank genomes that were previously reported in ClinVar, a database of clinically relevant genetic information (5) . The most recent variant adjudication was used for this analysis; approximately 90% of variants were adjudicated since 2015, the time when the ACMG guidelines were released (6) . African ancestry individuals are known to have greater genetic variation than either their European or Hispanic counterparts. Therefore, variant counts were divided by total variant count per person to account for this baseline difference across populations (28) . NUgene participants of African ancestry had more VUS compared to individuals of European, Hispanic and mixed ancestry even after normalization (p < 0.0001, Figure 2A ).
The NUgene genomes were then queried for nonsynonymous variation in the 59 medically-actionable genes ( Figure 2B) (7) . The mean normalized number of pathogenic and likely pathogenic variants in the 59 medically actionable gene lists did not differ across groups; however, the total number of these variants was very small. Within the medically-actionable genes, NUgene individuals of African ancestry were more likely to have VUS than individuals of European ancestry even after normalization to total variant count per person (p < 0.05, Figure   2B ). VUS numbers were similar between the other ancestry groups (Figure 2B) . The medically actionable genes were subdivided into cardiac and cancer genes and similarly analyzed (Supplemental Table 1 ). For cardiac medically actionable genes, African ancestry participants had more VUSs compared to European and mixed individuals even after normalization to total variant count (p < 0.05) ( Figure 2C ).
Medically actionable cardiac genes variants of uncertain significance correlate with left ventricular measures
Of the medically actionable genes, 30 are linked to cardiovascular conditions (Supplemental Table 1 ). The number of participants with ClinVar adjudicated pathogenic and likely pathogenic (P/LP) variants in these genes totaled 19 with no single individual having more than one P/LP variant ( Table 2) . Of these 19 individuals, 13 had an electrocardiogram, echocardiogram or test of their cholesterol level in the electronic health record, and those with electronic health cardiac data were ten years older than those without electronic health cardiac information (52 vs 42 years). Of the four individuals who had P/LP variants in long QT syndrome genes, all had a prolonged QTc ( Table 3) .
Because a proportion of VUS are likely to confer phenotype, VUS within the medicallyactionable cardiac genes were analyzed for their association with echocardiographic measures.
Of the 385 individuals with echocardiographic data in the electronic health records, 191 individuals had at least one VUS in the cardiac genes ( Table 2) To determine if these trends were driven by subjects with diagnosed cardiomyopathy, the electronic health record was queried for ICD-9 codes for cardiomyopathy including ICD-9 425. Ninety-four subjects were identified, including the original 56 pre-selected at the time of sequencing. The change in LV dimensions over time observed for the 94 cardiomyopathy subjects appeared similar to that of the entire cohort (Figure 4 and Table 4 ). However, none of these 94 individuals had a known pathogenic variant in the cardiac medically actionable gene list. Because there are more cardiomyopathy genes beyond those on the medically actionable list, we queried variation in 102 cardiomyopathy genes; this list of cardiomyopathy genes was derived from gene panels used in commercial testing labs (Supplemental Table 4 ). Only one individual had a pathogenic variant in the cardiac panel, TTR V122I, and a VUS in the cardiac medically actionable genes. Additional subjects with pathogenic variants lacked VUSs in the cardiac medically actionable genes and, therefore did not contribute to changes in LV dimensions seen in 
Evaluating variants unreported in ClinVar from diverse biobank participants
We next examined variants not previously reported in ClinVar. Across all genes, participants of African ancestry had more variants not previously reported in ClinVar (p < 0.0001, Supplemental Figure 4A ). For the medically actionable genes, there were similar numbers of variants not previously reported in ClinVar among all groups, when variant counts were normalized to the total number of variants per person found in these genes (Supplemental Figure 4B) . For cardiac actionable genes, African ancestry participants had fewer unreported variants compared to individuals of European and Hispanic ancestry when normalized to the total number of variants found in these genes (p < 0.0001 for both) (Supplemental Figure 4C) .
We evaluated the relationship between echocardiographic measurements and unreported variants in the cardiac medically-actionable genes ( Table 2 ). The genes with the most unreported variants were APOB, MYH11, and DSP (Supplemental Figure 5 ).
Longitudinal analyses of LVIDd, LVIDs, IVSDd, and LVEF, corrected for BSA, showed no difference over time when evaluating unreported rare variants. These analyses controlled for age at echocardiogram, sex, and self-reported race/ethnicity (Supplemental Table 3 ). While there may be variants of clinical impact in this dataset, the signal may be masked by the large number of benign variants.
Discussion
Clinically actionable findings in diverse biobank participants
The utility of genetic information improves with deeper and more diverse genetic databases.
This principle underlies All-of-Us, and the Million Veteran programs, which aim to provide a broader genetic picture of the diverse US population. For hypertrophic cardiomyopathy, it was previously suggested that the under-representation of participants from diverse racial and ethnic backgrounds in large public databases led to the misclassification of benign variants as pathogenic, especially in non-European ancestry populations (26) . In this study, individuals with pathogenic or likely pathogenic variants in the cardiac actionable genes had evidence of cardiac clinical findings in the electronic health record, and this was exemplified by the four diverse biobank participants with variants in genes linked to long QT syndrome. Because these variants increase risk for sudden death (29), these genetic findings represent an opportunity for risk reduction. These findings differ from a previous report where rare long QT syndromeassociated variants did not display clear differences from controls (30) . However, this current analysis relied more on ClinVar for interpretation, and during the intervening three years between the prior study and now, ClinVar has expanded with data contributions from more clinical testing and now includes many more variants interpreted through more consistent guidelines.
Racial differences in unreported variants
Given its composition, ClinVar's catalog of genetic variation, in part, reflects genetic testing practices (5) . The findings that European descent individuals are less likely to have unreported variants than other race/ethnic groups (p<0.001) may reflect that clinical genetic testing is disproportionally applied to this group. But this observation also likely reflects the smaller degree of genetic diversity within this group. Genetic diversity may contribute to disparity in interpreting genetic testing results in non-European and especially African ancestry individuals (31, 32) . This study showed that variants of uncertain significance were disproportionally higher in individuals of African ancestry than all other individuals, and this trend continued when the cardiac medical actionable genes were analyzed. However, this study also showed that individuals of African ancestry had fewer unreported variants in cardiac medically actionable genes when normalized to the total number of variants per person found in these genes. This may indicate that this disparity is more significant for genes which are not currently considered medically actionable. In addition, this information could also reflect the complexity in adjudicating variants in individuals of non-European ancestries, as this process is complicated by the high number of rare or private variants found in these populations, which is well positioned to contribute to interpretation as a VUS.
Variants of uncertain significance and echocardiographic findings
This study also identified echocardiographic findings associated with the presence of VUSs, suggesting that some VUSs influence cardiac phenotype. Left ventricular internal diameters, in diastole and systole, correlated with having 1 VUSs, and this result was especially evident in those with a cardiomyopathy diagnosis in the electronic health record. An array of cardiomyopathy genes, and other cardiac genes, harbored VUSs in these subjects, and MYBPC3 was noted as having the highest number of VUSs. MYBPC3 truncations are a common cause of hypertrophic cardiomyopathy (1, 33) , and the MYBPC3 VUSs were all missense, perhaps suggesting a distinct mode of action. In context of genetic testing for cardiomyopathies, variants of uncertain significance are typically returned and can sometimes be interpreted with further familial testing and segregation analysis (34, 35) . In the setting of biobank testing, such results would not be returned to subjects or providers, in part because interpretation of pathogenic variation is done outside the context of phenotype. We observed the correlation of VUS with LV dimensions, when viewing the entire cohort, but this finding was evident when considering only those with a cardiomyopathy diagnosis. The identification of genetic variants contributing to cardiomyopathy affects management, especially for the accompanying arrhythmia risk (1) . The inability to fully interpret these variants limits the use of this data for both the patients and their family members. Improved methods in which variants are interpreted in concert with clinical diagnoses may address this deficiency.
Uptick of genetic testing in the diverse clinical setting, along with stricter guidelines on interpretation, and the limitations of in silico tools have contributed to an increased number of uncertain variants (36, 37) . In practice, the enrichment of VUS in specific racial groups makes genetic testing harder to interpret within those groups. Expanding genetic databases to include self-reported race and ultimately linking this data to health information will facilitate genetic interpretation. The dataset developed in this report, along with the additional data generated from the eMERGE consortium, extends the diversity of publicly-available genetic information (16) . Until databases are sufficiently powered to address these deficiencies, in some cases, it may be reasonable to return VUS results to biobank participants, provided the biobank participants wish to receive these results. This would allow participants and their healthcare providers to assess risk by integrating this genetic data with personal medical findings and family medical history. Participants of self-reported African and Hispanic ancestry displayed a more heterogeneous genetic pattern for all variants. Self-reported race (colored circles) are displayed on a genetic clustering background and derived from self-report and grandparent race.
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Figure 2. African ancestry biobank participants have significantly more variants of uncertain significance (VUS). (A)
The average number of total nonsynonymous coding variants across all genes is shown for each group based on self-reported race. Variants of uncertain significance in ClinVar were greater in African ancestry biobank participants compared to other groups (p<0.0001, ANOVA across all groups). (B) The average number of nonsynonymous coding variants in the 59 medically actionable genes is shown by self-reported race. The number of variants of uncertain significance reported in ClinVar were greater in African ancestry biobank participants compared to all other groups (p<0.0001, ANOVA across all groups). (C) The average number of nonsynonymous coding variants in the 30 cardiac actionable genes is shown by self-reported race. The number of variants of uncertain significance reported in ClinVar were greater in African ancestry biobank participants compared to all other groups (p<0.0001, ANOVA across all groups). Supplemental Table 1 
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. Medically Actionable Genes by Cardiac and Cancer Designation
Cardiac Genes Cancer Genes
Other Genes  ACTA2  APC  ATP7B  ACTC1  BMPR1A  CACNA1S  APOB  BRCA1  OTC  COL3A1  BRCA2  RYR1  DSC2  MEN1  DSG2  MLH1  DSP  MSH2  FBN1  MSH6  GLA  MUTYH  KCNH2  NF2  KCNQ1  PMS2  LDLR  PTEN  LMNA  RB1  MYBPC3  RET  MYH11  SDHAF2  MYH7  SDHB  MYL2  SDHC  MYL3  SDHD  PCSK9  SMAD4  PKP2  STK11  PRKAG2  TP53  RYR2  TSC1  SCN5A  TSC2  SMAD3  VHL  TGFBR1  WT1  TGFBR2  TMEM43  TNNI3  TNNT2  TPM1 Supplemental A2ML1  CRYAB  FKRP  LAMP2  MYOZ  RAF1  TGFB3  ABCC9  CSRP3  FKTN  LDB3  MYPN  RASA1  TMEM43  ACTC1  CTF1  FLNC  LMNA  NEBL  RBM20  TMPO  ACTN2  CTNNA3 GAA  LRRC10 NEXN  RIT1  TNNC1  AGL  DES  GATA4  MAP2K1 NF1  RRAS  TNNI3  ALPK3  DMD  GATA6  MAP2K2 NKX2-5  RYR2  TNNT2  ANKRD1  DOLK  GATAD1 MIB1  NPPA  SCN5A  TPM1  BAG3  DSC2  GLA  MURC  NRAS  SGCD  TRDN  BRAF  DSG2  HCN4  MYBPC3 PDLIM3  SHOC2  TTN  CACNA1C DSP  HRAS  MYH6  PKP2  SLC22A5 TTR  CALR3  DTNA  ILK  MYH7  PLEKHM2 SOS1  TXNRD2  CASQ2  EMD  JPH2  MYL2  PLN  SOS2  VCL  CAV3  EYA4  JUP  MYL3  PRDM16  SPRED1  CBL  FHL1  KRAS  MYLK2  PRKAG2  TAZ  CHRM2 FHL2 LAMA4 MYOM1 PTPN11 TCAP Gene list ascertained by combining commercially available gene testing panels. 
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Supplemental Figure 4. African ancestry biobank participants have significantly more unreported variants (URV). (A)
The average number of total nonsynonymous coding variants across all genes is shown for each group based on self-reported race. Unreported variants (URV) in ClinVar were greater in African ancestry biobank participants compared to other groups (p<0.0001, ANOVA across all groups). (B) The average number of nonsynonymous coding variants in the 59 medically actionable genes is shown by self-reported race. The number of unreported variants (URV) in ClinVar were less in African ancestry biobank participants compared to all other groups (p<0.0001, ANOVA across all groups). (C) The average number of nonsynonymous coding variants in the 30 cardiac actionable genes is shown by self-reported race. The number of unreported variants (URV) in ClinVar were less in African ancestry biobank participants compared to all other groups (p<0.0001, ANOVA across all groups).
